LIST OF VOLUNTARY STUDY MEMBERS, ALL FROM AUSTRIA

Agnes Scharrer	Liesa-Marie Schreiber
Albert Falch	Lisa-Maria Raschbichler
Alina Mracsna	Magdalena Fruhwirth
Anastasia von Canal	Maria Holzknecht
Anna Haslwanter	Maria Huber
Benedikt Leonhard	Martin Anegg
Bianca Neurauter	Martin Klieber
Brigitte Müllauer	Mathias Baumgartner
Carina Praxmarer	Michael Unterhofer
David Bante	Nina Fernbach
David Bante Eva Hochmuth	Nina Fernbach Rosmarie Gstraunthaler
David Bante Eva Hochmuth Fatima Aslam	Nina Fernbach Rosmarie Gstraunthaler Sophia Schmidt
David Bante Eva Hochmuth Fatima Aslam Frederik Radvan	Nina Fernbach Rosmarie Gstraunthaler Sophia Schmidt Teresa Harthaller
David Bante Eva Hochmuth Fatima Aslam Frederik Radvan Hanna Salvotti	Nina Fernbach Rosmarie Gstraunthaler Sophia Schmidt Teresa Harthaller Theodora Todorovic
David Bante Eva Hochmuth Fatima Aslam Frederik Radvan Hanna Salvotti Jonas Huber	Nina FernbachRosmarie GstraunthalerSophia SchmidtTeresa HarthallerTheodora TodorovicTheresa Genser
David Bante Eva Hochmuth Fatima Aslam Frederik Radvan Hanna Salvotti Jonas Huber Katharina Wagner	Nina FernbachRosmarie GstraunthalerSophia SchmidtTeresa HarthallerTheodora TodorovicTheresa GenserValentin Schiessendoppler
David Bante Eva Hochmuth Fatima Aslam Frederik Radvan Hanna Salvotti Jonas Huber Katharina Wagner Lena Hinterstoisser	Nina FernbachRosmarie GstraunthalerSophia SchmidtTeresa HarthallerTheodora TodorovicTheresa GenserValentin SchiessendopplerVerena Söll

Supplementary methods

Peripheral blood mononuclear cell (PBMC) isolation

40 ml of whole blood was collected in 9 ml S-Monovette[®] EDTA tubes (Sarstedt, Nümbrecht, Gemany). PBMCs were isolated by layering 20 ml EDTA blood on 15 ml Pancoll human (PAN-Biotech, Aidenbach, Germany) and subsequent density-gradient centrifugation for 30 minutes at 1800 rpm. PBMCs were collected from the interphase, washed twice in PBS and counted. PBMCs were cryopreserved in heat-inactivated fetal calf serum (FCS, Gibco) supplemented with 10% DMSO (Gibco) and stored in liquid nitrogen until use.

Interferon-y (IFNy) ELISPOT assay following 7-day in vitro expansion

Following 7-day *in vitro* expansion, cells were harvested, counted and analyzed in an IFN γ enzymelinked immunospot (ELISPOT) assay (ImmunoSpot®, C.T.L. Europe, Bonn, Germany) according to the manufacturer's protocol. Briefly, a total of 1×10^5 cells per well were placed in anti-human IFN γ mAbcoated plates in 100 µL RPMI medium supplemented with 2% human AB serum and were re-stimulated with or without 1 µg/ml pepS, pepM or pepN peptide pools. As positive controls, cells were stimulated with 10 µg/ml PHA or re-stimulated with PepTivator pepCEF at 1 µg/ml. After 24 h incubation, IFN γ producing cells were visualized by staining with anti-human IFN γ -FITC, FITC-HRP and substrate solution according to the manufacturer's protocol. Spots were counted using an ImmunoSpot® S5 analyzer (C.T.L. Europe, Bonn, Germany). IFN γ -producing spot forming cells (SFC) per 1×10⁶ cells corresponding to specific T cell responses were calculated from the number of SFCs after specific stimulation minus SFCs of negative control without stimulation. Stimulations were considered reactive when spot count was higher than the mean of the spot count plus 1×SD of the study negative group after the respective stimulation.

Intracellular cytokine staining

SARS-CoV-2 peptide-specific T cells were further characterized by intracellular (IC) cytokine and cell surface staining. For intracellular cytokine and cell surface staining after 7-days *in vitro* expansion, 1×10^5 cells per well in 100 µL RPMI medium supplemented with 2% human AB serum were restimulated with or without 1 µg/ml pepS, pepM or pepN peptide pools. As positive controls, cells were either stimulated with 10 µg/ml PHA or re-stimulated with PepTivator pepCEF at 1 µg/ml. After 3.5 hours, BD GolgiPlugTM protein transport inhibitor (BD Austria, Vienna) was added according to the manufacturer's instructions. After an 18-hour incubation, surface staining was performed with PE-Cy7 anti-human CD3 (clone SK7), BV510 anti-human CD4 (clone SK3) and BV421 anti-human CD8 (clone RPA-T8) monoclonal antibodies all purchased from BD (BD Austria, Vienna). For live/dead staining BD HorizonTM Fixable Viability Stain 780 (BD Austria, Vienna) was used according to the manufacturer's instructions. IC staining was performed using BD Cytofix/CytopermTM fixation/permeabilization kit (BD Austria, Vienna) according to the manufacturer's instructions using BD FastImmuneTM PE anti-human IFN γ (clone 25723.11) and APC anti-human TNF α (clone 6401.1111) antibodies (BD Austria, Vienna). All samples were measured on a BD FACSCantoTM II cytometer (BD) and data were analyzed using FlowJo v10 software (BD).

Supplementary Table 1. Study population

	Baseline	Baseline	Lost to	New at	Excluded	Total	T Cell
	(Adults)*	Analysis	Follow-up [#]	Follow-up ^{\$}	(Follow-up	Follow-up	Sample [§]
		Sample			sample)		
		(Adults)**					
Number of							
participants, n (%)							
Male	604 (48.0)	361 (45.1)	238 (53.4)	52 (57.8)	5 (41.7)	413 (46.4)	48 (51.6)
Female	653 (51.9)	440 (54.9)	206 (46.2)	38 (42.2)	7 (58.3)	478 (53.7)	45 (48.4)
Diverse	2 (0.2)	0 (0.0)	2 (0.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Age (years), mean							
(SD), median							
Male	44.9 (16.2)	45.5 (15.6)	43.7 (16.9)	43.4 (19.7)	54.2 (29.4)	45.2 (16.3)	45.1 (12.5)
	44.0	46.0	41.0	41.5	43.0	45.0	47.0
Female	45.6 (16.7)	45.7 (16.0)	45.6 (17.9)	39.7 (18.4)	44.6 (24.1)	45.2 (16.1)	42.8 (13.8)
	45.0	45.0	43.5	35.0	40.0	45.0	42.0
Adults (≥ 18)	45.2 (16.5)	45.6 (15.8)	44.5 (17.4)	41.8 (19.2)	48.6 (25.6)	45.2 (16.2)	44.0 (13.1)
	44.0	45.0	42.0	39.5	46.5	45.0	45.0
Age at Baseline							
(years)							
distribution, n (%)							
18-24	135 (10.7)	80 (10.0)	52 (11.7)	24 (26.7)	3 (25.0)	104 (11.7)	7 (7.5)
25-34	256 (20.3)	148 (18.5)	107 (24.0)	19 (21.1)	1 (8.3)	167 (18.7)	18 (19.4)
35-44	243 (19.3)	157 (19.6)	84 (18.8)	7 (7.8)	2 (16.7)	164 (18.4)	21 (22.6)
45-54	239 (19.0)	153 (19.1)	85 (19.1)	13 (14.4)	1 (8.3)	166 (18.6)	26 (28.0)
55-64	220 (17.5)	167 (20.9)	52 (11.7)	15 (16.7)	1 (8.3)	182 (20.4)	17 (18.3)
65-74	110 (8.7)	71 (8.9)	37 (8.3)	7 (7.8)	2 (16.7)	78 (8.8)	3 (3.2)
≥ 75	56 (4.5)	25 (3.1)	29 (6.5)	5 (5.6)	2 (16.7)	30 (3.4)	1 (1.1)
Total	1259	801	446	90	12	891	93
P-value (Baseline		0.0	01†				
v Analysis Sample							
- Sex)							

- Sex)
* All participants ≥ 18, which were included in baseline study; ** participants, which participated in both studies; # participants, which did not come back to the follow-up study; \$ participants, which entered the study at follow-up study, analysed at follow-up time point, § Sub-population used for T cell analysis in follow-up study; ⁺ Fisher's exact

	n	Baseline (Median (IQR))	Follow-up (Median (IQR))	Wilcoxon signed rank p-value	%decrease in median
Euroimmun	801	0.6 (0.2-3.6)	0.3 (0.1-1.3)	<0.000	50.0
Abbott	801	0.9 (0.0-5.8)	0.1 (0.0-0.7)	<0.000	88.9
Roche	40	29.0 (8.9-50.4)	12.0 (4.0-35.0)	<0.000	58.6

Supplementary Table 2. Change in median IgG antibody titers from baseline to follow-up

IQR = interquartile range

Supplementary Table 3. Seroprevalence

Sample	Baseline (Adults)*	Baseline Analysis Sample (Adults)**	Follow-up Analysis Sample [#]	New at Follow-up ^{\$}	All Adults at Follow-up
% positive	45.0	51.4	45.4	37.8	44.7
(number positive/total number)	(566/1259)	(412/801)	(364/801)	(34/90)	(398/891)
95% Confidence Interval	42.2 - 47.8	47.9-54.9	42.0 - 49.0	27.6 - 48.6	41.4 - 48.0

* All participants ≥ 18, which were included in baseline study, analysed at baseline time point; ** participants, which participated in both studies, analysed at baseline time point; # participants, which participated in both studies, analysed at follow-up time point; \$ participants, which entered the study at follow-up time, analysed at follow-up time point

Supplementary Table 4: Potential new infections between baseline and follow-up

Sex	Age⁺	Antibody baseline (I1)			Antibody follow-up (I2)			Serostatus ^{\$}	positive PCR	Symptoms
		Anti S IgG	Anti N IgG	Neutralization	Anti S IgG	Anti N IgG	Neutralization		between	between
		(OD ratio)*	(RLU)**	assay [§]	(OD ratio)*	(RLU)**	assay [§]		I1 and I2 [#]	I1 and I2 [#]
male	25-34	0.195	0.0	≤1:4	2.830	5.8	1:256	n-p	-	Cough
male	45-54	0.325	0.1	≤1:4	4.149	7.3	1:16	n-p	-	Fever, headache,
										irritated eyes, sore
										throat, running
										nose
female	55-64	0.203	0.0	≤1:4	2.662	0.7	1:64	n-d	-	Sleep disturbance
male	25-34	0.075	0.0	≤1:4	1.638	2.0	1:64	n-p	+	Cold, sore throat,
									10/2020	running nose

* at baseline; * OD ratio >0.8= positive ; ** RLU >1.4 positive; [§]cutoff: >1:4=positive, ≤1:4=negative; [#] self-reported; ^{\$} p = positive, d = discrepant, a = IgA only, n = negative OD= optical density. RLU= relative light unit. S= spike protein. N= nucleocapsid protein



Supplementary Figure 1. Study enrolment follow-up (Ischgl 2)



Supplementary Figure 2. T cell responses against positive controls. (a) IFN γ ELISPOT assay and (b) IFN γ /TNF α intracellular cytokine (IC) staining after a 7-day *in vitro* expansion followed by re-stimulation with pepCEF peptide pool and PHA as positive controls. Values after stimulation were normalized to non-stimulated samples in both ELISPOT and IC stainings. (a) Shown are IFN γ positive SFCs per 10⁶ cells in baseline negative and positive study groups (serostatus at follow-up study either positive p or discordant d) after stimulation with pepCEF (upper graph) or PHA (lower graph). (b) Percentage of IFN γ /TNF α -producing CD3+ total T cells, CD3+CD4+ helper T cells and CD3+CD8+ cytotoxic T cells after are shown. After IC staining living/singlet cells were gated for CD3+ total, CD3+CD4+ and CD3+CD8+ T cells and the indicated percentage depicts the frequency of IFN γ /TNF α double-positive cells in the respective population of the sample stimulated with pepCEF or PHA minus the frequency of the non-stimulated control.